This is my today´s mail to Paul Cataford. It may give some ideas for others to contact Titan:
Dear Mr. Cataford,
My family has invested into Titan medical since 2015. For the time being we own 400 Thousand shares.
With reference to your Investor presentation dated January 4th 2022, I kindly ask you to answer the following questions. Far too often long term investors like us experienced informations which shortly after turned out to be not correct or even false. If you and Titan´s management team are interested to win back investors trust I strongly recommend to give transparency high priority.
1. What exactly means "Complete development of the Enos system"? Repeatedly Titan has deceived investors by saying development is complete. I can not see why we should buy now in such an objective without knowing exactly what needs further development.
2. What exactly has been developed by: "Completed Under Medtronic
Collaboration and was achieved by milestone 4"? It can not be that one of the most important achievements and thus material information is still blinded to the owners of the company.
3. Which patents exactly have been licensed to Medtronic? Without such knowledge it simply is not possible for us imvestors being the owners of Titan, to calculate a realistic value potential of the IP portfolio.
4. What reasons make you believe That "Targeting a 15-month time-line to human clinical trials" is realistic and can be achieved?
5. Why is Titan still heading for an FDA approval first, whereas many companioes, e. g. MDT, give first priority to CE Mark approval?
Dear Mr. Cataford, I could easily add several additional questions. I strongly believe if Titans communication will not dramatically improve, Titan will fail to gain investor´s support.
Sincerely
Best regards to all Longs
Facetrain
